Pro-inflammatory cytokines and inflammatory signaling pathways

Pro-inflammatory cytokines and inflammatory signaling pathways encompass a diverse group of signaling molecules and intracellular cascades that drive the body's immune response to harmful stimuli (StatPearls, 2023). This broad category includes key cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as primary messengers in the inflammatory process (Nature Reviews Immunology, 2018). These ligands bind to specific cell-surface receptors, triggering downstream signaling pathways like NF-kappaB, MAPK, and JAK-STAT to modulate gene expression (PubMed, 2021). While these pathways are essential for host defense and wound healing, their chronic or excessive activation is a central driver of autoimmune diseases, chronic inflammatory conditions, and systemic inflammatory response syndromes (NIH, 2022). Therapeutic strategies targeting these pathways include monoclonal antibodies that neutralize specific cytokines and small-molecule inhibitors that target intracellular kinases (Frontiers in Immunology, 2020). However, because these pathways are integral to normal immune function, their inhibition can lead to significant safety concerns, most notably an increased susceptibility to opportunistic infections and the potential for impaired tumor surveillance.

Other names

Inflammatory mediatorsPro-inflammatory signalingCytokine signaling cascadesInflammatory cascade

Neutralization of pro-inflammatory ligands, competitive antagonism of cytokine receptors, and inhibition of intracellular signaling kinases (e.g., JAK inhibitors) to prevent gene transcription of inflammatory mediators.